X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs IPCA LABS - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA IPCA LABS AUROBINDO PHARMA/
IPCA LABS
 
P/E (TTM) x 16.2 28.9 56.1% View Chart
P/BV x 4.1 3.4 119.0% View Chart
Dividend Yield % 0.4 0.1 279.4%  

Financials

 AUROBINDO PHARMA   IPCA LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
IPCA LABS
Mar-18
AUROBINDO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs895695 128.7%   
Low Rs622400 155.5%   
Sales per share (Unadj.) Rs254.6260.2 97.8%  
Earnings per share (Unadj.) Rs39.319.0 207.0%  
Cash flow per share (Unadj.) Rs46.633.1 140.9%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.30.2 180.5%  
Book value per share (Unadj.) Rs160.0213.0 75.1%  
Shares outstanding (eoy) m585.88126.20 464.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.1 141.5%   
Avg P/E ratio x19.328.9 66.9%  
P/CF ratio (eoy) x16.316.6 98.3%  
Price / Book Value ratio x4.72.6 184.4%  
Dividend payout %6.45.3 120.8%   
Avg Mkt Cap Rs m444,39069,120 642.9%   
No. of employees `00014.013.3 105.5%   
Total wages/salary Rs m17,6787,359 240.2%   
Avg. sales/employee Rs Th10,667.82,477.4 430.6%   
Avg. wages/employee Rs Th1,264.3555.2 227.7%   
Avg. net profit/employee Rs Th1,645.8180.6 911.1%   
INCOME DATA
Net Sales Rs m149,15732,836 454.3%  
Other income Rs m1,159418 277.2%   
Total revenues Rs m150,31633,254 452.0%   
Gross profit Rs m34,3434,505 762.4%  
Depreciation Rs m4,2761,777 240.6%   
Interest Rs m667240 277.8%   
Profit before tax Rs m30,5582,905 1,051.8%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597511 1,486.3%   
Profit after tax Rs m23,0122,394 961.2%  
Gross profit margin %23.013.7 167.8%  
Effective tax rate %24.917.6 141.3%   
Net profit margin %15.47.3 211.6%  
BALANCE SHEET DATA
Current assets Rs m92,06219,455 473.2%   
Current liabilities Rs m66,22310,076 657.3%   
Net working cap to sales %17.328.6 60.6%  
Current ratio x1.41.9 72.0%  
Inventory Days Days10698 108.3%  
Debtors Days Days6867 101.1%  
Net fixed assets Rs m62,91920,260 310.6%   
Share capital Rs m586252 232.1%   
"Free" reserves Rs m93,13326,633 349.7%   
Net worth Rs m93,71926,886 348.6%   
Long term debt Rs m1,8142,340 77.5%   
Total assets Rs m162,49441,173 394.7%  
Interest coverage x46.813.1 357.4%   
Debt to equity ratio x00.1 22.2%  
Sales to assets ratio x0.90.8 115.1%   
Return on assets %14.66.4 227.7%  
Return on equity %24.68.9 275.7%  
Return on capital %32.710.8 304.2%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m75,83815,642 484.8%   
Fx outflow Rs m30,2244,884 618.9%   
Net fx Rs m45,61310,759 424.0%   
CASH FLOW
From Operations Rs m32,7863,411 961.1%  
From Investments Rs m-17,870-1,354 1,319.8%  
From Financial Activity Rs m-19,153-1,304 1,468.6%  
Net Cashflow Rs m-4,239753 -562.8%  

Share Holding

Indian Promoters % 54.1 45.9 117.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 11.4 69.7%  
FIIs % 27.7 25.3 109.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.4 58.6%  
Shareholders   69,601 36,892 188.7%  
Pledged promoter(s) holding % 8.6 2.1 400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  PIRAMAL ENTERPRISES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS